%0 Journal Article
%T Clinical impact of different detection methods for disseminated tumor cells in bone marrow of patients undergoing surgical resection of colorectal liver metastases: a prospective follow-up study
%A F Jeroen Vogelaar
%A Wilma E Mesker
%A Arjen M Rijken
%A Gaby W van Pelt
%A Antonia M van Leeuwen
%A Hans J Tanke
%A Rob A Tollenaar
%A Gerrit J Liefers
%J BMC Cancer
%D 2010
%I BioMed Central
%R 10.1186/1471-2407-10-153
%X Sixty patients with colorectal liver metastases were planned for a curative resection between 2001 and 2007. All patients underwent bone marrow aspiration before surgery. Detection of tumor cells was performed using immunocytochemical staining for cytokeratin (CK-ICC) combined with automated microscopy or indirectly using reverse transcription-polymerase chain reaction (RT-PCR).Disseminated tumor cells were found in 15 of the 46 patients (33%) using CK-ICC and in 9 of 44 of the patients (20%) using RT-PCR. Patients with negative results for RT-PCR had a significant better disease-free survival after resection of their liver metastases (p = 0.02). This group also showed significant better overall survival (p = 0.002). CK-ICC did not predict a worse clinical outcome.The presence of disseminated tumor cells in bone marrow detected using RT-PCR did predict a worse clinical outcome. The presence of cells detected with CK-ICC did not correlate with poor prognosis.Over the past decades surgical resection has evolved as the first choice of treatment for colorectal liver metastases because it is a relatively safe and potentially curative procedure [1,2]. The reported 3-year survival of patients after surgical resection of colorectal liver metastasis ranges from 57% to 73% [3,4]. However, even after curative surgical resection, a high percentage of patients show recurrent disease, either in the liver or extra hepatic, within a relatively short period of time after surgical treatment [5] caused by minimal residual disease (MRD) [6]. These high-risk patients might benefit from additional systemic treatment [7]. Currently available prognostic factors are insufficient to select patients at risk for tumor progression [8]. Therefore the need for additional methods for the selection of high-risk patients is evident.On a clinical level, the Memorial Sloan-Kettering Cancer Center Clinical Risk Score (MSKCC-CRS) is a frequently used tool to predict the risk for recurrence and tumor pro
%U http://www.biomedcentral.com/1471-2407/10/153